Introduction:
NLC Health Ventures and Verily have partnered together to launch Exvolvo Biosciences, a biotech company that aims to provide a next-generation solution for biologic drug delivery through oral administration. Exvolvo’s technology offers a flexible capsule size and modular design, allowing it to adapt to a variety of large molecule structures. The company is focused on making treatments more accessible and less invasive for patients with chronic diseases.
- NLC Health Ventures and Verily have partnered to launch Exvolvo Biosciences.
- Exvolvo aims to provide a next-generation solution for biologic drug delivery through oral administration.
- The technology offers a flexible capsule size and modular design.
- The company aims to make treatments more accessible and less invasive for patients with chronic diseases.
- Exvolvo is actively engaging with key pharma and biotech partners and progressing towards assembling an IND package in the US.
Conclusion:
NLC Health Ventures and Verily’s partnership to launch Exvolvo Biosciences offers an innovative solution for biologic drug delivery. The company’s flexible capsule size and modular design differentiate it in the industry and position it at the forefront of oral drug delivery innovation. This technology has the potential to significantly impact patient treatment experiences and increase efficiency in healthcare delivery. Exvolvo’s progress towards assembling an IND package and engagement with key partners demonstrates its commitment to advancing drug delivery options.
